文献速递甲状腺核医学肿瘤 PET/CT

[18F]氟胆碱PET/CT在MEN1相关原发性甲状旁腺功能亢进症初次手术前或持续性/复发性疾病中的表现

Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-07

回顾性法国多中心研究纳入71例MEN1相关原发性甲状旁腺功能亢进症患者(73次PET/CT),评估[18F]氟胆碱PET/CT在不同疾病阶段的检测性能。患者层面灵敏度为98.5%至100%,病灶层面灵敏度为84.4%至87%、特异度为94.7%至98.8%,观察者间一致性高。PET/CT检测到的病灶多于常规影像检查。

要点

  • 患者层面[18F]氟胆碱PET/CT灵敏度为98.5%至100%(不同阅片者)。
  • 病灶层面(41例手术患者)灵敏度84.4%至87%,特异度94.7%至98.8%。
  • PET/CT检测到的病灶多于常规影像检查(颈部超声和/或闪烁显像)。

核心结论

  • [18F]氟胆碱PET/CT是评估MEN1相关原发性甲状旁腺功能亢进症的可靠且稳健的影像学方法,可指导外科医生实现最佳获益-风险比。
  • 本研究为其在该背景下作为主要诊断工具的应用提供了很大推动力。

研究设计与样本

  • 回顾性法国多中心研究,纳入71例MEN1相关原发性甲状旁腺功能亢进症患者(共73次PET/CT),在初次诊断时或评估持续性/复发性疾病时行[18F]氟胆碱PET/CT。
  • PET/CT由两名阅片者以盲法独立审阅。
  • 患者层面的评估采用一套综合标准,考虑病理发现或非手术患者中与替代诊断方法的一致性。
  • 次要目标包括以病理金标准为参照分析病灶层面的性能,并检查观察者间可重复性。

主要发现

  • 患者层面(整个队列)[18F]氟胆碱PET/CT灵敏度在不同阅片者间为98.5%至100%。
  • 每次PET平均描述1.77个腺体,初次诊断时为2.35个腺体(n=23),既往手术病例中为1.5个(n=50)。
  • PET/CT检测到的病灶多于常规影像检查(颈部超声和/或闪烁显像)。
  • 病灶层面(41例手术患者)灵敏度在不同阅片者间为84.4%至87%,特异度为94.7%至98.8%。
  • 初次诊断时,PET显示3个或以上异常腺体的所有患者均接受了甲状旁腺次全切除术,而PET显示1或2个腺体异常的13例患者中有7例接受了低于次全切除术的手术。

关键数值与推荐

  • 患者层面灵敏度:不同阅片者为98.5%至100%。
  • 病灶层面(41例手术患者):灵敏度84.4%至87%,特异度94.7%至98.8%。
  • 每次PET平均描述1.77个腺体;初次诊断时2.35个腺体(n=23),既往手术病例中1.5个(n=50)。

临床怎么用

  • 原文结论指出[18F]氟胆碱PET/CT可指导外科医生在MEN1相关原发性甲状旁腺功能亢进症中实现最佳获益-风险比。
  • 原文结论认为本研究为其在该背景下作为主要诊断工具的应用提供了很大推动力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aims of the study were to evaluate the performance and robustness of [18F]fluorocholine PET/CT in detecting hyperfunctioning parathyroid glands in MEN1-related primary hyperparathyroidism (pHPT) at different stages of their disease. METHODS: Retrospective French multicenter study including patients with MEN1 pHPT who underwent [18F]fluorocholine PET/CT at initial diagnosis or for evaluation of persistent/recurrent disease. PET/CT were independently reviewed by two readers in a blinded manner. The assessment of PET/CT on a per-patient basis was assessed using a comprehensive set of criteria that considered pathological findings or agreement with alternative diagnostic methods in non-operated patients. The secondary objectives included the analysis of the performance of PET/CT at a per-lesion level, with reference to a pathological Gold Standard, and examining its interobserver reproducibility. RESULTS: A total of 71 MEN1 patients were included (73 PET/CT) in the study. At the per-patient level (entire cohort), [18F]fluorocholine PET/CT sensitivity ranged from 98.5 to 100% among the different readers. An average of 1.77 glands per PET was described, with 2.35 glands at the initial diagnosis (n = 23) and 1.5 in previously operated cases (n = 50). PET/CT detected more lesions than conventional imaging work-up (neck ultrasound and/or scintigraphy). At the per-lesion level (41 operated patients), sensitivity ranged across different readers from 84.4 to 87%, and specificity ranged from 94.7 to 98.8%. At initial diagnosis, all patients that exhibited 3 or more abnormal glands on PET underwent subtotal parathyroidectomy while 7 out of 13 patients with 1 or 2 gland abnormalities on PET underwent less than subtotal parathyroidectomy. Finally, the degree of inter-observer agreement was high. CONCLUSION: [18F]fluorocholine PET/CT is a reliable and robust imaging modality for the evaluation of MEN1-related pHPT and could guide surgeons in achieving the optimal benefit-risk ratio. This study gives a great impetus for its adoption as a primary diagnostic tool in this context.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Boucher A, Delabie J, Lussey-Lepoutre C, et al. Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease. Eur J Nucl Med Mol Imaging. 2023. PMID: 38057652. doi:10.1007/s00259-023-06537-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。